Pharmaceuticals

Nippon Kayakuʼs efforts towards cancer treatment have provided numerous products since the launch of BLEO.

A large lineup of cancer-related products and accumulation of information as well as know-how are our strong points. In the cancer-related field, we aim to contribute to society through improved medical care by promoting innovations in our proprietary technologies and by providing a stable supply of and information about high quality pharmaceutical products. We do this by stationing cancer-specialist medical representatives throughout Japan, setting up Medical Information Service Centers, where we respond to inquiries from medical professionals and others, and preparing a framework that can deliver information to medical institutions about correct drug use for assisting in medical treatment.

医薬品

Introduction of Main Products

Anti-cancer drugs

Nippon Kayaku's involvement with anti-cancer drugs dates back to 1969, when it released bleomycin. After that, the company has continued its research and development of therapeutic agents for the improvement of cancer treatment. As of September 2023, Nippon Kayaku has launched 50 anti-cancer drugs and cancer-related drugs, including generics.

History of anti-cancer and cancer-related drugs at Nippon Kayaku

The company's strength lies in its extensive line of anti-cancer drugs and expertise.

医薬品

(as of January, 2024)

Cancer-related drugs

In addition to anti-cancer drugs, Nippon Kayaku also researches, develops, and sells other drugs used in cancer treatment. These typically include a pain relief drug to relieve the pain caused by metastatic bone cancer.

Biosimilars

Nippon Kayaku aims to make further contributions to patients, their families, and healthcare professionals through the rapid commercialization of biosimilar pharmaceuticals, which are playing a major role in the treatment of cancer and Autoimmune disease. By providing a wide range of biosimilars, the company hopes to help realize a society where everyone has access to high quality medical care, at any place and time.

History of Biosimilars at Nippon Kayaku

医薬品

(as of January, 2024)

Generic drugs

Nippon Kayaku is also engaged in the development of generic drugs. Since there are a large number of drugs involved in cancer treatment, including anti-cancer and anti-emetic drugs, in these generic drugs, the company has worked to further expand its lineup of cancer medications.

Other pharmaceuticals

In addition to cancer-related drugs, Nippon Kayaku is engaged in the development and manufacturing of other pharmaceuticals, such as cardiovascular treatments.

Related Information

Our Business

PageTop
Our Business
R&D
Corporate Information
Global Netowork
Investor Relations
Sustainability